HIGHLIGHTS
- who: Neurofibromatosis and collaborators from the This Article was downloaded from Harvard University's DASH repository, and is made available , Hamburg, Germany have published the article: Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2, in the Journal: (JOURNAL)
- what: The authors report the clinical effect of bevacizumab on ependymomas in 8 patients with NF2, and VEGF receptor expression in 5 resected, NF2-related ependymomas.
SUMMARY
Neurofibromatosis type 2 (NF2) is a neurogenetic tumor predisposition disorder with an incidence of ~1:27,000. In most NF2 patients, spinal ependymomas are . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.